Trial Profile
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I/II Clinical Trial
Status:
Not yet recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Netarsudil (Primary)
- Indications Proliferative vitreoretinopathy; Retinal detachment
- Focus Adverse reactions; Pharmacokinetics
- 09 Jan 2024 Planned initiation date changed from 1 Oct 2023 to 1 Feb 2024.
- 18 Sep 2023 New trial record